Publication Feature: Harvard-MIT CRS enables adaptive clinical trial in glioblastoma
Adaptive clinical trials are a novel randomized clinical trial (RCT) design which enables the study of multiple interventions in a disease in a perpetual manner, with interventions entering and leaving the platform based on a predefined decision algorithm. A new Nature Perspectives article defines best practices for launching adaptive clinical trials.
This publication resulted from a 2017 workshop hosted by Harvard-MIT CRS, which formed the Adaptive Platform Trial (APT) Coalition to enable the design and implementation of innovative clinical trials for novel therapies and as alternatives to traditional RCTs. The guidance produced during the meeting gathered support from clinicians, investigators, sponsors and regulators, highlighting the need to build a flexible and sustainable infrastructure to support such trials. As a result, the Global Coalition for Adaptive Research was created to operationalize the conduct of APTs and to accelerate the discovery and development of cures for patients with rare and deadly diseases. The world’s first global adaptive clinical trial platform for glioblastoma, GBM AGILE, started enrolling patients this year.
The article describing the challenges and opportunities of APTs and can be read here.